Key result
Early RV free wall strain reduction linked to ~39% higher odds of anthracycline cardiotoxicity.
Why the study?
Although early detection and prediction of LV dysfunction has been widely studied in patients receiving anthracyclines, little is known about early changes in RV size and function in this population.
Does 3-dimensional echocardiography predict anthracycline-induced right ventricular cardiotoxicity in patients with diffuse large B-cell lymphoma?
Cohort (n=74)
Blinded outcome assessment (sonographers and off-line echocardiography readers blinded to clinical data)
No
Does 3-dimensional echocardiography predict anthracycline-induced right ventricular cardiotoxicity in patients with diffuse large B-cell lymphoma?
Early changes in 3D echocardiography-derived right ventricular longitudinal free wall strain and end-systolic volume can predict subsequent anthracycline-induced right ventricular cardiotoxicity.
Answers are grounded in this paper and cite their sources.
May support early 3DE RV monitoring in anthracycline-treated DLBCL; hypothesis-generating and requires prospective validation before practice change.
OBJECTIVES: The purpose of this study was to assess the associations between 3-dimensional echocardiography (3DE)-derived changes in right ventricular (RV) volumes and strains with subsequent RV cardiotoxicity in patients treated with anthracyclines. BACKGROUND: Although early detection and prediction of left ventricular (LV) dysfunction has been widely studied in patients receiving anthracyclines, little is known about the early changes in RV size and function in this population. METHODS: A total of 74 patients with diffuse large B-cell lymphoma who received 6 cycles of anthracycline-based treatment were enrolled. Echocardiography was performed at baseline or before chemotherapy (pre-chemotherapy) (T0); after 2 cycles (T1); after 4 cycles (T2); and at the end of 6 cycles of chemotherapy (T3). Right ventricular end-diastolic volume (RVEDV), end-systolic volume (RVESV), ejection fraction (RVEF), longitudinal free wall strain (RVLFS), and longitudinal septal strain (RVLSS) were quantified by 3DE. RV cardiotoxicity was defined as a relative reduction of >10% in 3D RVEF or a relative reduction of >5% to a value of <45%. Volume status was assessed by inferior vena cava diameter (IVCD) and the estimated right atrial pressure (RAP). RESULTS: Twenty-seven patients developed cardiotoxicity after 6 cycles of chemotherapy (T3). Compared to baseline, increases in 3D RVEDV (58.5 ± 7.7 ml vs. 64.2 ± 7.0 ml; p < 0.001) and RVESV (27.8 ± 4.2 ml vs. 31.3 ± 4.2 ml; p < 0.001) were observed by the end of the fourth cycle of chemotherapy (T2). 3D RVLFS (-27.3 ± 3.1% vs. -24.2 ± 2.6%; p < 0.001) was also decreased at T2 compared to baseline. Statistically significant declines in 3D RVLSS (-26.1 ± 2.5% vs. -22.9 ± 2.7%; p < 0.001) and RVEF (54.0 ± 2.8% vs. 49.8 ± 2.4%; p < 0.001) were only observed at T3. A relative decrease in RVLFS of >12.4% (sensitivity, 78.6%; specificity, 82.6%; area under the curve (AUC), 0.80; p < 0.001); and a relative increase in RVESV of >13.2% (sensitivity, 71.4%; specificity, 71.7%; AUC, 0.76; p <0.001) from baseline to T2 predicted subsequent RV cardiotoxicity at T3. IVCD and RAP did not change significantly over time. CONCLUSIONS: 3DE-derived measurements of RV strain and volume were associated with subsequent changes in RVEF. With further study, RVLFS and RVESV could potentially be used to predict subsequent declines in RVEF with anthracyclines.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2020) conducted a cohort in Diffuse large B-cell lymphoma receiving anthracycline-based chemotherapy (n=74). 3DE-derived percentage change in RV longitudinal free wall strain (ΔRVLFS) and RV end-systolic volume (ΔRVESV) after 4 cycles of anthracycline chemotherapy vs. Baseline (pre-chemotherapy) 3DE RV parameters / patients without RV cardiotoxicity was evaluated on Prediction of anthracycline-induced right ventricular cardiotoxicity (defined as >10% relative reduction in 3D RVEF or >5% relative reduction to <45% at the end of 6 cycles) by ΔRVLFS from baseline to cycle 4 (OR 1.393, 95% CI 1.093-1.692, p=0.001). 3DE-derived relative decreases in RV longitudinal free wall strain >12.4% and increases in RVESV >13.2% after 4 cycles predicted subsequent RV cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: